Actively Recruiting
The Role of IL-23 in Chronic Inflammatory Disease: Exploring the Cellular and Molecular Targets of IL-23 Signaling in Peripheral and Axial Spondyloarthritis
Led by Institut Pasteur · Updated on 2025-01-23
90
Participants Needed
4
Research Sites
260 weeks
Total Duration
On this page
Sponsors
I
Institut Pasteur
Lead Sponsor
J
Janssen Biotech, Inc.
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a research study involving humans, of the interventional type with minimal risks and constraints (RIPH2). It is a multicentric, non randomized prospective study aiming to better understand the mechanisms of the response to anti-IL-23 biologics in Spondyloarthritis patients attending the rheumatology department of Cochin, Saint-Antoine, Henri-Mondor hospitals (APHP) and Maison-Blanche Hospital (Reims).
CONDITIONS
Official Title
The Role of IL-23 in Chronic Inflammatory Disease: Exploring the Cellular and Molecular Targets of IL-23 Signaling in Peripheral and Axial Spondyloarthritis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults older than 18 years
- Diagnosed with Spondyloarthritis according to ASAS criteria
- Have active disease with signs such as active synovitis, tendinitis, dactylitis, or significant inflammatory spinal pain
- Able to provide informed consent
- Covered by health insurance (except AME beneficiaries)
For patients with axial SpA (Group 1):
- Biologic therapy naive
For patients with peripheral SpA or psoriatic arthritis (Group 2):
- Diagnosed with peripheral SpA or psoriatic arthritis with peripheral joint inflammation
- Require synovial fluid aspiration as part of standard care
You will not qualify if you...
- Under 18 years of age
- Pregnant or breastfeeding
- Immunocompromised
- Have received two or more biologic therapies
- Receiving corticosteroid treatment over 10 mg per day
- Under legal protection such as guardianship or curatorship
- Refuse to give consent
- Have a history of alcoholism, drug addiction, psychological problems, or severe conditions that may affect consent or protocol compliance
- Beneficiary of AME
For patients with axial SpA (Group 1):
- Have received any biological therapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Hôpital Henri-Mondor, AP-HP - Service de Rhumatologie
Créteil, France, 94000
Not Yet Recruiting
2
Hôpital Cochin, AP-HP - Department of Dermatology B
Paris, France
Actively Recruiting
3
Hôpital Saint-Antoine, AP-HP - Service de Rhumatologie
Paris, France
Actively Recruiting
4
Hôpital Maison Blanche - Service de Rhumatologie
Reims, France, 51092
Not Yet Recruiting
Research Team
L
Lars ROGGE, Dr
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here